ECSP13012983A - Nuevos acidos piperidinil-monocarboxilicos como agonistas del receptor de esfingosina-1-fosfato-1(s1p1) - Google Patents
Nuevos acidos piperidinil-monocarboxilicos como agonistas del receptor de esfingosina-1-fosfato-1(s1p1)Info
- Publication number
- ECSP13012983A ECSP13012983A ECSP13012983A ECSP13012983A EC SP13012983 A ECSP13012983 A EC SP13012983A EC SP13012983 A ECSP13012983 A EC SP13012983A EC SP13012983 A ECSP13012983 A EC SP13012983A
- Authority
- EC
- Ecuador
- Prior art keywords
- sphingosine
- phosphate
- new
- piperidinil
- receptor agonists
- Prior art date
Links
- 239000002253 acid Substances 0.000 title 1
- 150000007513 acids Chemical class 0.000 title 1
- 239000000018 receptor agonist Substances 0.000 title 1
- 229940044601 receptor agonist Drugs 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 3
- 102000011011 Sphingosine 1-phosphate receptors Human genes 0.000 abstract 1
- 108050001083 Sphingosine 1-phosphate receptors Proteins 0.000 abstract 1
- 239000000556 agonist Substances 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 238000002360 preparation method Methods 0.000 abstract 1
- DUYSYHSSBDVJSM-KRWOKUGFSA-N sphingosine 1-phosphate Chemical compound CCCCCCCCCCCCC\C=C\[C@@H](O)[C@@H](N)COP(O)(O)=O DUYSYHSSBDVJSM-KRWOKUGFSA-N 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
- C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
- C07D271/06—1,2,4-Oxadiazoles; Hydrogenated 1,2,4-oxadiazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Oncology (AREA)
- Pulmonology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Diabetes (AREA)
- Communicable Diseases (AREA)
- Neurology (AREA)
- Urology & Nephrology (AREA)
- Dermatology (AREA)
- Hematology (AREA)
- Rheumatology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Transplantation (AREA)
- Endocrinology (AREA)
- Virology (AREA)
- Vascular Medicine (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Obesity (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Hospice & Palliative Care (AREA)
Abstract
La presente invención se refiere a nuevos compuestos que actúan como agonistas de los receptores de S1P (esfingosina-1-fosfato), a composiciones que contienen estos compuesto, al uso de estos compuestos en medicina y su proceso de preparación.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP11305433A EP2511275A1 (en) | 2011-04-12 | 2011-04-12 | Novel piperidinyl monocarboxylic acids as S1P1 receptor agonists |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ECSP13012983A true ECSP13012983A (es) | 2014-05-31 |
Family
ID=43984071
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ECSP13012983 ECSP13012983A (es) | 2011-04-12 | 2013-10-21 | Nuevos acidos piperidinil-monocarboxilicos como agonistas del receptor de esfingosina-1-fosfato-1(s1p1) |
Country Status (25)
| Country | Link |
|---|---|
| US (1) | US9266867B2 (es) |
| EP (2) | EP2511275A1 (es) |
| JP (1) | JP6050315B2 (es) |
| KR (1) | KR101854152B1 (es) |
| CN (1) | CN103619838B (es) |
| AU (1) | AU2012241981B2 (es) |
| BR (1) | BR112013026434B1 (es) |
| CA (1) | CA2833180C (es) |
| CO (1) | CO6801772A2 (es) |
| DK (1) | DK2697219T3 (es) |
| EA (1) | EA023638B1 (es) |
| EC (1) | ECSP13012983A (es) |
| ES (1) | ES2544616T3 (es) |
| HU (1) | HUE025443T2 (es) |
| IL (1) | IL228844A (es) |
| MA (1) | MA35305B1 (es) |
| MX (1) | MX342926B (es) |
| PH (1) | PH12013502142A1 (es) |
| PL (1) | PL2697219T3 (es) |
| PT (1) | PT2697219E (es) |
| SG (1) | SG194183A1 (es) |
| TN (1) | TN2013000425A1 (es) |
| UA (1) | UA110822C2 (es) |
| WO (1) | WO2012140020A1 (es) |
| ZA (1) | ZA201307820B (es) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112019000486A2 (pt) | 2016-07-13 | 2019-04-24 | Leo Pharma A/S | composto, composição farmacêutica, e, método para prevenir, tratar ou melhorar psoríase |
| CN111807954B (zh) * | 2019-04-10 | 2024-04-05 | 广东东阳光药业股份有限公司 | 一种辛波莫德中间体的制备方法 |
| TWI825672B (zh) * | 2021-04-14 | 2023-12-11 | 南韓商Ｌｇ化學股份有限公司 | 製備用於合成神經鞘胺醇－１－磷酸酯受體促效劑的中間體之方法 |
| CN113332435B (zh) * | 2021-06-18 | 2022-10-18 | 广州中医药大学(广州中医药研究院) | 鞘氨醇-1-磷酸4受体激动剂及其与真武汤联合在制备治疗慢性肾小球肾炎药物中的应用 |
| JP2025525896A (ja) * | 2022-08-01 | 2025-08-07 | コリア・インスティテュート・オブ・サイエンス・アンド・テクノロジー | 新規なヘテロシクリル－フェニル－メチルアミン誘導体、その製造方法及びその多発性硬化症予防、改善、又は治療用途 |
| WO2025083549A1 (en) | 2023-10-16 | 2025-04-24 | Sun Pharma Advanced Research Company Limited | Methods and combinations of inhibitors of il-23 pathway and modulators of s1p signaling pathway for the treatment of autoimmune disorders |
| CN117623967A (zh) * | 2023-11-16 | 2024-03-01 | 迪嘉药业集团股份有限公司 | 一种替米沙坦中间体3-甲基-4-氨基苯甲酸的制备方法 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7479504B2 (en) * | 2002-01-18 | 2009-01-20 | Merck & Co., Inc. | Edg receptor agonists |
| JP2005533058A (ja) * | 2002-06-17 | 2005-11-04 | メルク エンド カムパニー インコーポレーテッド | Ｅｄｇ受容体アゴニストとしての１−（（５−アリール−１，２，４−オキサジアゾール−３−イル）ベンジル）アゼチジン−３−カルボキシラートおよび１−（（５−アリール−１，２，４−オキサジアゾール−３−イル）ベンジル）ピロリジン−３−カルボキシラート |
| EP2021338A1 (en) | 2006-05-09 | 2009-02-11 | Pfizer Products Inc. | Cycloalkylamino acid derivatives and pharmaceutical compositions thereof |
| BRPI0720043A2 (pt) * | 2006-12-15 | 2014-01-07 | Abbott Lab | Composto oxadiazol |
| EP2014653A1 (en) * | 2007-06-15 | 2009-01-14 | Bioprojet | Novel dicarboxylic acid derivatives as S1P1 receptor agonists |
| EP2193125B1 (en) * | 2007-10-04 | 2017-01-11 | Merck Serono S.A. | Oxadiazole derivatives |
| GB0725102D0 (en) * | 2007-12-21 | 2008-01-30 | Glaxo Group Ltd | Compounds |
| AU2009323259A1 (en) * | 2008-12-05 | 2011-06-23 | Astellas Pharma Inc. | 2H-chromene compound and derivative thereof |
| EP2305660A1 (en) * | 2009-09-25 | 2011-04-06 | Almirall, S.A. | New thiadiazole derivatives |
| EP2366702A1 (en) * | 2010-03-18 | 2011-09-21 | Almirall, S.A. | New oxadiazole derivatives |
| ME02556B (me) * | 2011-02-07 | 2017-02-20 | Biogen Ma Inc | Agensi koji moduliraju s1 p |
-
2011
- 2011-04-12 EP EP11305433A patent/EP2511275A1/en not_active Withdrawn
-
2012
- 2012-04-10 EA EA201301150A patent/EA023638B1/ru not_active IP Right Cessation
- 2012-04-10 CA CA2833180A patent/CA2833180C/en active Active
- 2012-04-10 KR KR1020137030008A patent/KR101854152B1/ko active Active
- 2012-04-10 EP EP12714674.4A patent/EP2697219B1/en active Active
- 2012-04-10 MX MX2013011984A patent/MX342926B/es active IP Right Grant
- 2012-04-10 WO PCT/EP2012/056470 patent/WO2012140020A1/en not_active Ceased
- 2012-04-10 JP JP2014504282A patent/JP6050315B2/ja active Active
- 2012-04-10 PL PL12714674T patent/PL2697219T3/pl unknown
- 2012-04-10 PT PT127146744T patent/PT2697219E/pt unknown
- 2012-04-10 PH PH1/2013/502142A patent/PH12013502142A1/en unknown
- 2012-04-10 SG SG2013076591A patent/SG194183A1/en unknown
- 2012-04-10 DK DK12714674.4T patent/DK2697219T3/en active
- 2012-04-10 ES ES12714674.4T patent/ES2544616T3/es active Active
- 2012-04-10 BR BR112013026434-9A patent/BR112013026434B1/pt active IP Right Grant
- 2012-04-10 US US14/111,438 patent/US9266867B2/en active Active
- 2012-04-10 CN CN201280022925.5A patent/CN103619838B/zh active Active
- 2012-04-10 AU AU2012241981A patent/AU2012241981B2/en active Active
- 2012-04-10 HU HUE12714674A patent/HUE025443T2/en unknown
- 2012-10-04 UA UAA201313012A patent/UA110822C2/uk unknown
-
2013
- 2013-10-13 IL IL228844A patent/IL228844A/en active IP Right Grant
- 2013-10-14 TN TNP2013000425A patent/TN2013000425A1/fr unknown
- 2013-10-21 ZA ZA2013/07820A patent/ZA201307820B/en unknown
- 2013-10-21 EC ECSP13012983 patent/ECSP13012983A/es unknown
- 2013-10-22 MA MA36356A patent/MA35305B1/fr unknown
- 2013-11-12 CO CO13265458A patent/CO6801772A2/es not_active Application Discontinuation
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ECSP13012983A (es) | Nuevos acidos piperidinil-monocarboxilicos como agonistas del receptor de esfingosina-1-fosfato-1(s1p1) | |
| CR20140185A (es) | Derivados de (4-fenilimidazol-2-il)etilamina útiles como moduladores de canal de sodio | |
| UY33317A (es) | Nuevos derivados de pirazol | |
| ECSP10010169A (es) | Composiciones que comprenden moduladores del receptor de fosfato de esfingosina-1 (s1p) | |
| CR20140182A (es) | Nuevos derivados de ciclohexilamina que tienen actividad como agonistas adrenérgicos b2 y como antagonistas muscarínicos m3 | |
| CR20140181A (es) | Nuevos derivados de ciclohexilamina que tienen actividad como agonistas adrenérgicos b2 y como antagonistas muscarínicos m3 | |
| GT201400136A (es) | Compuestos y métodos de benzaldehído substituído para su uso en incrementar la oxigenación de los tejidos | |
| ECSP13012519A (es) | Compuestos sustituidos de benzamida | |
| CR20130671A (es) | Antagonistas de trpv4 | |
| GT201300196A (es) | Moduladores del receptor de glucagón | |
| SV2010003738A (es) | Derivados de indazoles sustituidos con fenilo o piridinilo | |
| CO6592031A2 (es) | Nuevos derivados de cocloheliamina que tienen actividad como agonistas adrenérgicos b2 y como antagonistas muscarínicos m3 | |
| UY32853A (es) | Nuevos compuestos de oxadiazol | |
| CO6640327A2 (es) | Compuestos de pirazol como inhibidores del receptor sigma | |
| NI201500080A (es) | Nuevos derivados carbamato de ciclohexilo y quinuclidinilo que tienen actividad como agonistas b2 adrenérgicos y como antagonistas muscarínicos m3. | |
| EA201690006A1 (ru) | Сухая порошковая композиция, содержащая антихолинергический агент, кортикостероид и бета-адренергический агент, для введения путем ингаляции | |
| CR20120542A (es) | HETEROARIL-CICLOHEXIL-TETRAAZABENZO [e] AZULENOS | |
| UY36979A (es) | Compuestos de criptoficina novedosos y productos conjugados, su preparación y su uso terapéutico | |
| CR20160084A (es) | Derivados de amida como agonistas del receptor del ácido lisofosfatídico | |
| ECSP13013012A (es) | Análogos del ácido epoxieicosatrienoicos y métodos de preparación | |
| CR20150322A (es) | Nuevos derivados carbamato de ciclohexilo y quinuclidinilo que tienen actividad como agonistas b2 adrenérgicos y como antagonistas muscarínicos m3 | |
| UY32734A (es) | Compuestos agonistas del receptor esfingosina 1-fosfato | |
| CO6351723A2 (es) | Derivados de pirazolo-[5,1-b]-oxazol como antagonistas de crf1 | |
| CR20140257A (es) | Nuevos 2h-indazoles como antagonistas del receptor ep2 | |
| MX2013012025A (es) | Moduladores novedosos de neutransmision cortical dopaminergica y glutamatergica mediada por receptor de n-metil-d-aspartato. |